KMDA Kamada Ltd. - Ordinary Shares

+0.05  (1%)
Previous Close 7.10
Open 7.15
Price To book 4.06
Market Cap 258.50M
Shares 36,154,000
Volume 2,997
Short Ratio 1.35
Av. Daily Volume 5,386

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated April 2016
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
PDUFA date August 29, 2017.
Prophylaxis of rabies disease
Top-line data released August 30, 2016. Primary endpoint met. Pivotal trial planned for 2018.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2/3 data due mid-2017.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Announced November 2, 2016 that Phase 2/3 enrollment to start imminently with data due 2020.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)